New Alzheimer’s blood test may tell when symptoms are around the corner
Clinical Scorecard: Innovative Blood Test for Alzheimer’s Could Predict Onset of Symptoms
At a Glance
| Category | Detail |
|---|
| Condition | Alzheimer's Disease |
| Key Mechanisms | Elevated levels of circular RNAs (circRNAs) in blood as predictors of symptom onset. |
| Target Population | Individuals at risk of developing Alzheimer's disease symptoms. |
| Care Setting | Clinical research and trials. |
Key Highlights
- New biomarker shows potential to predict imminent Alzheimer's symptoms.
- CircRNAs may reflect recent brain activity, unlike traditional amyloid plaque markers.
- Study analyzed blood data from over 1,200 individuals across multiple cohorts.
- CircRNA model outperformed existing pTau217 model in predicting disease progression.
- Findings suggest circRNA levels diverge from normal 2-4 years before symptom onset.
Guideline-Based Recommendations
Diagnosis
- Utilize circRNA levels for early identification of Alzheimer's disease pathology.
Management
- Consider circRNA testing for selecting candidates for clinical trials and monitoring treatment response.
Monitoring & Follow-up
- Monitor circRNA levels to assess disease progression and treatment efficacy.
Risks
- Potential for misinterpretation of circRNA levels in the context of ongoing treatments.
Patient & Prescribing Data
Patients at risk for Alzheimer's disease.
CircRNAs may provide a more comprehensive view of disease biology, especially in patients treated with amyloid-targeting therapies.
Clinical Best Practices
- Incorporate circRNA testing in clinical settings for better prediction of Alzheimer's symptoms.
- Use circRNA levels to guide treatment decisions and clinical trial eligibility.
Related Resources & Content
